Login to Your Account



CuraGen, Bayer Advance Four Compounds Through Screening

By Kim Coghill


Friday, February 1, 2002
One year after signing a $1.4 billion agreement aimed at developing 12 drugs in obesity and diabetes, CuraGen Corp. and partner Bayer Corp. said they have successfully completed screening against four targets. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription